Evidence is mounting that the CD44+CD24−/low cell subpopulation, which is enriched with potential breast cancer stem cells (CSCs), could explain clinical resistance to HER2-targeted therapies [1-3]. The gene discussed is CD44; the disease is breast carcinoma.